发布求助
文献互助 智能选刊 最新文献

Leukemia & Lymphoma最新文献

筛选
英文 中文
Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma. 新型疗法在复发/难治性弥漫大B细胞淋巴瘤中的实际疗效。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2024-11-01 Epub Date: 2024-07-16 DOI: 10.1080/10428194.2024.2371472
Jennifer L Crombie, Monika Jun, Tongsheng Wang, Alex Mutebi, Anthony Wang, Anindit Chhibber, Rajesh Kamalakar, Jon Ukropec, Julie Blaedel, Anupama Kalsekar
{"title":"Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma.","authors":"Jennifer L Crombie, Monika Jun, Tongsheng Wang, Alex Mutebi, Anthony Wang, Anindit Chhibber, Rajesh Kamalakar, Jon Ukropec, Julie Blaedel, Anupama Kalsekar","doi":"10.1080/10428194.2024.2371472","DOIUrl":"10.1080/10428194.2024.2371472","url":null,"abstract":"<p><p>This study used COTA de-identified data (2010-2021) of patients in the US to explore outcomes of novel therapies in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in real-world settings. Demographics, clinical characteristics, and clinical outcomes of patients with R/R DLBCL who received novel treatments including chimeric antigen receptor T-cell (CAR T) therapy and tafasitamab- or polatuzumab-based therapies were evaluated. Overall, 175 patients with R/R DLBCL were analyzed; 73, 69, and 27 received CAR T therapy, polatuzumab-based regimens, and tafasitamab-based regimens, respectively. In patients who had ≥1 prior lines of therapy (i.e. starting second-line or later therapy; 2 L+), CAR T, polatuzumab-based regimens, and tafasitamab-based regimens achieved a median overall survival of 26.5, 7.8, and 6.3 months, respectively. Outcomes were particularly poor for patients with relapse following CAR T, indicating that polatuzumab- and tafasitamab-based regimens in 2 L + R/R DLBCL have suboptimal outcomes in the real world. Additional treatment options are needed.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sarcopenia is a prognostic factor in lymphoma patients: a systematic review and meta-analysis. 肌肉疏松症是淋巴瘤患者的预后因素：系统综述与荟萃分析。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2024-11-01 Epub Date: 2024-07-31 DOI: 10.1080/10428194.2024.2371500
Yixuan Li, Qi Sheng, Jiayao Li, Wenyu Liu, Li Ma, Lei Han, Juan He, Ting Zhao, Yuning Chu
{"title":"Sarcopenia is a prognostic factor in lymphoma patients: a systematic review and meta-analysis.","authors":"Yixuan Li, Qi Sheng, Jiayao Li, Wenyu Liu, Li Ma, Lei Han, Juan He, Ting Zhao, Yuning Chu","doi":"10.1080/10428194.2024.2371500","DOIUrl":"10.1080/10428194.2024.2371500","url":null,"abstract":"<p><p>Findings regarding the relationship between sarcopenia and lymphoma have been inconsistent across studies. This study investigated the association between sarcopenia and lymphoma. We systematically searched the Embase, Science Direct, Cochrane Library, and PubMed databases from inception to 31 March 2024 to identify relevant studies. Two researchers independently extracted and evaluated studies that met inclusion and exclusion criteria. Twenty-six studies with 3659 participants were included. Sarcopenic lymphoma patients had poor overall survival (OS) (HR = 1.88; 95% CI: 1.47-2.41; <i>p</i> < 0.001). The heterogeneity was high (I<sup>2</sup>=80%). However, the result of the Egger test indicated a significant publication bias (<i>p</i> < 0.001). After employing the trim and fill method to adjust for this bias, the HR of OS became non-significant (<i>p</i> > 0.05). The progression-free survival (PFS) was worse in sarcopenic patients (HR = 1.77; 95% CI: 1.37-2.29; <i>p</i> < 0.001; I<sup>2</sup>=70%). There was no significant publication bias (<i>p</i> > 0.05). In the subgroup analyses, sarcopenia was a negative predictor of OS in lymphoma patients who undergo hematopoietic cell transplantation (HCT) (HR  = 1.61;95% CI: 1.19-2.18; I<sup>2</sup>=30%). Male lymphoma patients with sarcopenia had a significantly worse OS (HR = 2.29; 95% CI:1.24-4.24; <i>p</i> = 0.009). Among patients with primary central nervous system lymphoma (PCNSL), those with sarcopenia defined by temporal muscle thickness (TMT) exhibited significantly worse OS (HR = 2.20; 95% CI:1.04-4.65; <i>p</i> = 0.039; I<sup>2</sup>=68%). Sarcopenia is associated with worse PFS in lymphoma patients. Subgroup analyses indicate that sarcopenia is a negative predictor of OS after HCT, and male lymphoma patients who suffer from sarcopenia have higher mortality. Sarcopenia defined by TMT is also a negative predictor of OS for patients with PCNSL.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141860194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characteristics, treatment, and outcomes of mantle cell lymphoma with cutaneous involvement: a decade-long study at MD Anderson cancer center. 皮肤受累的套细胞淋巴瘤的特征、治疗和预后：MD 安德森癌症中心长达十年的研究。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2024-11-01 Epub Date: 2024-07-07 DOI: 10.1080/10428194.2024.2374457
Jared R Zhang, Susan Y Wu, Preetesh Jain, Chi Young Ok, Fangfang Yan, Wendy Chen, Onyeka Oriabure, Bouthaina Dabaja, Jillian Gunther, Penny Fang, Chelsea Pinnix, Michael L Wang, Charles Gaulin
{"title":"Characteristics, treatment, and outcomes of mantle cell lymphoma with cutaneous involvement: a decade-long study at MD Anderson cancer center.","authors":"Jared R Zhang, Susan Y Wu, Preetesh Jain, Chi Young Ok, Fangfang Yan, Wendy Chen, Onyeka Oriabure, Bouthaina Dabaja, Jillian Gunther, Penny Fang, Chelsea Pinnix, Michael L Wang, Charles Gaulin","doi":"10.1080/10428194.2024.2374457","DOIUrl":"10.1080/10428194.2024.2374457","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141555162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiation therapy for the management of T cell cutaneous lymphomas. Updated results of the role of low dose total skin electron beam (TSEB) therapy. 治疗T细胞皮肤淋巴瘤的放射治疗。低剂量全皮肤电子束（TSEB）疗法作用的最新结果。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2024-11-01 Epub Date: 2024-07-07 DOI: 10.1080/10428194.2024.2374049
Ioannis Georgakopoulos, Kalliopi Platoni, Lia Papadavid, Efrosini Kypraiou, George Patatoukas, Andromachi Kougioumtzopoulou, Marios Koumourtzis, Vassilis Kouloulias
{"title":"Radiation therapy for the management of T cell cutaneous lymphomas. Updated results of the role of low dose total skin electron beam (TSEB) therapy.","authors":"Ioannis Georgakopoulos, Kalliopi Platoni, Lia Papadavid, Efrosini Kypraiou, George Patatoukas, Andromachi Kougioumtzopoulou, Marios Koumourtzis, Vassilis Kouloulias","doi":"10.1080/10428194.2024.2374049","DOIUrl":"10.1080/10428194.2024.2374049","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141555165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring SARS-CoV-2 infection and vaccine-induced immunity in chronic myeloid leukemia patients: insights from real-world data in Brazil and the United States. 探索慢性髓性白血病患者的 SARS-CoV-2 感染和疫苗诱导免疫：从巴西和美国的实际数据中获得的启示。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2024-11-01 Epub Date: 2024-07-05 DOI: 10.1080/10428194.2024.2367057
Ana Carolina Mourão Toreli, Marisol Miranda-Galvis, Muhannad Sharara, Marcelo Addas-Carvalho, Eliana Miranda, Leonardo Fechio, Adriana Silva Santos Duarte, Audrey Basso, Gislaine Duarte, Samuel Souza Medina, Fernando Pericole, Bruno Benites, Kimya Jones, Harmanpreet Singh, Jaspreet Farmaha, Ashutosh Vashisht, Ravindra Kolhe, Ashis K Mondal, Sara Teresinha Olalla Saad, Carmino Antonio de Souza, Jorge E Cortes, Katia Pagnano
{"title":"Exploring SARS-CoV-2 infection and vaccine-induced immunity in chronic myeloid leukemia patients: insights from real-world data in Brazil and the United States.","authors":"Ana Carolina Mourão Toreli, Marisol Miranda-Galvis, Muhannad Sharara, Marcelo Addas-Carvalho, Eliana Miranda, Leonardo Fechio, Adriana Silva Santos Duarte, Audrey Basso, Gislaine Duarte, Samuel Souza Medina, Fernando Pericole, Bruno Benites, Kimya Jones, Harmanpreet Singh, Jaspreet Farmaha, Ashutosh Vashisht, Ravindra Kolhe, Ashis K Mondal, Sara Teresinha Olalla Saad, Carmino Antonio de Souza, Jorge E Cortes, Katia Pagnano","doi":"10.1080/10428194.2024.2367057","DOIUrl":"10.1080/10428194.2024.2367057","url":null,"abstract":"<p><p>This study investigates COVID-19 outcomes and immune response in chronic myeloid leukemia (CML) patients post-SARS-CoV-2 vaccination, comparing effectiveness of various vaccine options. Data from 118 CML patients (85 in Brazil, 33 in the US) showed similar infection rates prior (14% Brazil, 9.1% US) and post-vaccination (24.7% vs. 27.3%, respectively). In Brazil, AstraZeneca and CoronaVac were the most commonly used vaccine brands, while in the US, Moderna and Pfizer-BioNTech vaccines dominated. Despite lower seroconversion in the Brazilian cohort, all five vaccine brands analyzed prevented severe COVID-19. Patients who received mRNA and recombinant viral vector vaccines (HR: 2.20; 95%CI 1.07-4.51; <i>p</i> < .031) and those that had achieved at least major molecular response (HR: 1.51; 95% CI 1.01-3.31; <i>p</i> < .0001) showed higher seroconversion rates. Our findings suggest that CML patients can generate antibody responses regardless of the vaccine brand, thereby mitigating severe COVID-19. This effect is more pronounced in patients with well-controlled disease.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141534753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High red cell mass and high plasma volume are independently associated with thrombotic risk in polycythemia vera. 高红细胞质量和高血浆容量与多发性红细胞症的血栓风险有独立关联。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2024-11-01 Epub Date: 2024-06-20 DOI: 10.1080/10428194.2024.2368639
Ivan Krecak, Danijela Lekovic, Andrija Bogdanovic, Marko Lucijanic
{"title":"High red cell mass and high plasma volume are independently associated with thrombotic risk in polycythemia vera.","authors":"Ivan Krecak, Danijela Lekovic, Andrija Bogdanovic, Marko Lucijanic","doi":"10.1080/10428194.2024.2368639","DOIUrl":"10.1080/10428194.2024.2368639","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141427114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Importance of long-term follow-up of autologous stem cell transplantation for mantle cell lymphoma. 套细胞淋巴瘤自体干细胞移植长期随访的重要性。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2024-11-01 Epub Date: 2024-07-05 DOI: 10.1080/10428194.2024.2373323
Colin Stewart, Carolyn Owen, Neil Chua, Anthea Peters, Mona Shafey, Alex Balogh, Jeffrey Cao, Douglas Stewart, Robert Puckrin
{"title":"Importance of long-term follow-up of autologous stem cell transplantation for mantle cell lymphoma.","authors":"Colin Stewart, Carolyn Owen, Neil Chua, Anthea Peters, Mona Shafey, Alex Balogh, Jeffrey Cao, Douglas Stewart, Robert Puckrin","doi":"10.1080/10428194.2024.2373323","DOIUrl":"10.1080/10428194.2024.2373323","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141534754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updated quality of life data from the phase 3b VENICE II trial: patients with relapsed or refractory chronic lymphocytic leukemia receiving venetoclax monotherapy. 3b 期 VENICE II 试验的最新生活质量数据：接受 Venetoclax 单药治疗的复发性或难治性慢性淋巴细胞白血病患者。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2024-11-01 Epub Date: 2023-08-25 DOI: 10.1080/10428194.2023.2247511
Tara Cochrane, Alicia Enrico, David Gomez-Almaguer, Evgueniy Hadjiev, Ewa Lech-Maranda, Tamas Masszi, Eugene Nikitin, Tadeusz Robak, Robert Weinkove, Shang-Ju Wu, Beenish S Manzoor, Todd Busman, Madhavi Pai, Viktor Komlosi, Mary Ann Anderson
{"title":"Updated quality of life data from the phase 3b VENICE II trial: patients with relapsed or refractory chronic lymphocytic leukemia receiving venetoclax monotherapy.","authors":"Tara Cochrane, Alicia Enrico, David Gomez-Almaguer, Evgueniy Hadjiev, Ewa Lech-Maranda, Tamas Masszi, Eugene Nikitin, Tadeusz Robak, Robert Weinkove, Shang-Ju Wu, Beenish S Manzoor, Todd Busman, Madhavi Pai, Viktor Komlosi, Mary Ann Anderson","doi":"10.1080/10428194.2023.2247511","DOIUrl":"10.1080/10428194.2023.2247511","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10070331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of chronic graft-versus-host disease on non-relapse mortality and survival. 慢性移植物抗宿主疾病对非复发死亡率和存活率的影响。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2024-11-01 Epub Date: 2024-06-12 DOI: 10.1080/10428194.2024.2365910
Justin Jiang, Audrey M Sigmund, Qiuhong Zhao, Patrick Elder, Sumithira Vasu, Samantha Jaglowski, Alice Mims, Hannah Choe, Karilyn Larkin, Sarah Wall, Nicole Grieselhuber, Basem William, Sam Penza, Don M Benson, Yvonne A Efebera, Nidhi Sharma
{"title":"Impact of chronic graft-<i>versus</i>-host disease on non-relapse mortality and survival.","authors":"Justin Jiang, Audrey M Sigmund, Qiuhong Zhao, Patrick Elder, Sumithira Vasu, Samantha Jaglowski, Alice Mims, Hannah Choe, Karilyn Larkin, Sarah Wall, Nicole Grieselhuber, Basem William, Sam Penza, Don M Benson, Yvonne A Efebera, Nidhi Sharma","doi":"10.1080/10428194.2024.2365910","DOIUrl":"10.1080/10428194.2024.2365910","url":null,"abstract":"<p><p>Chronic graft-<i>versus</i>-host-disease (cGVHD) is one of the primary causes of morbidity and mortality for patients who undergo allogeneic hematopoietic stem cell transplantation (allo-HCT). In recent years, advancements in allo-HCT have allowed a broader range of patients to receive transplant, particularly older patients. We sought to assess the impact of cGVHD on outcomes in patients undergoing allo-HCT, for older patients as compared to their counterparts. We performed a retrospective analysis of all patients who underwent allo-HCT 1999-2018. Our results showed that those patients who developed cGVHD by <i>D</i> + 180 had an increased risk and incidence of NRM as compared to those patients without cGVHD. There was no significant difference in outcomes for those patients with cGVHD by age (≥60 years old [yo] and <60 yo). These findings suggest the significant morbidity of cGVHD, regardless of age.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141306254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polycythemia vera: past, present and future. 多发性红细胞症：过去、现在和未来。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2024-11-01 Epub Date: 2024-06-13 DOI: 10.1080/10428194.2024.2361836
Ami B Patel, Lucia Masarova, Ruben A Mesa, Gabriela Hobbs, Naveen Pemmaraju
{"title":"Polycythemia vera: past, present and future.","authors":"Ami B Patel, Lucia Masarova, Ruben A Mesa, Gabriela Hobbs, Naveen Pemmaraju","doi":"10.1080/10428194.2024.2361836","DOIUrl":"10.1080/10428194.2024.2361836","url":null,"abstract":"<p><p>There has been remarkable progress in the development of novel therapeutic approaches for patients with polycythemia vera (PV). Historically, therapy goals in PV were to mitigate thrombotic risks and control blood counts and symptoms. There is now increased focus on disease modification through progressive attrition of <i>JAK2</i>-mutant stem/progenitor cells. The approval of ropeginterferon, a novel monoPEGylated interferon, coupled with findings from LOW-PV and longer-term data from CONTINUATION-PV that strongly support a disease-modifying effect for interferon therapy, have transformed the treatment paradigm for this disorder. Results from MAJIC-PV demonstrate that disease modification can also be induced with JAK inhibitors, suggesting an urgent need to incorporate prospective molecular monitoring into PV trials. Novel agents, such as hepcidin mimetics, aim to help patients with PV restore normal hematocrit levels and become phlebotomy-free. In this review, we will summarize past, current and future approaches to PV management and highlight findings from key clinical studies.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141317608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信